Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. September 23, 2010 By Bio-Medicine.Org ‘/>”/> SOURCE
